Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel

Tsai, Max; Lu, Ze; Wang, Jie; Yeh, Teng‐Kuang; Wientjes, M. Guillaume; Au, Jessie L.-S.

doi:10.1007/s11095-007-9298-0

Cited by 115 publications

(114 citation statements)

References 32 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…In our opinion, this slower clearance rate can be attributed to the aggregation of these nanoparticles to micrometer sized particles in the IP fluid. As has been suggested, these microparticles do indeed show a slower clearance rate from the IP cavity when compared to nanoparticles [59].…”

Section: Tailoring Delivery Systems For Ip Therapysupporting

confidence: 53%

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

et al. 2014

View full text Add to dashboard Cite

Intraperitoneal (IP) administration of nano-sized delivery vehicles containing small interfering RNA (siRNA) is recently gaining attention as an alternative route for the efficient treatment of peritoneal carcinomatosis. The colloidal stability of nanomatter following IP administration has, however, not been thoroughly investigated yet. Here, enabled by advanced microscopy methods such as Single Particle Tracking (SPT) and Fluorescence Correlation Spectroscopy (FCS), we follow the aggregation and cargo release of nano-scaled systems directly in peritoneal fluids from healthy mice and ascites fluid from a patient diagnosed with peritoneal carcinomatosis. The colloidal stability in the peritoneal fluids was systematically studied in function of the charge (positive or negative) and Poly-Ethylene Glycol (PEG) degree of liposomes and polystyrene nanoparticles, and compared to human serum. Our data demonstrate strong aggregation of cationic and anionic nanoparticles in the peritoneal fluids, while only slight aggregation was observed for the PEGylated ones. PEGylated liposomes, however, lead to a fast and premature release of siRNA cargo in the peritoneal fluids. Based on our observations, we reflect on how to tailor improved delivery systems for IP therapy.

show abstract

Section: Tailoring Delivery Systems For Ip Therapysupporting

confidence: 53%

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…MPs were retained in the peritoneal cavity for a longer time period, but a high incidence of adhesions 2 weeks after injection of the MPs made them unsuitable for long term delivery to the peritoneum [61]. Similarly, Tsai et al examined the effect of carrier size on the disposition and anti-tumor activity of paclitaxel (PTX) [62]. In particular, PTX loaded gelatin MPs and NPs, as well as Cremophor micelles were systematically studied in mice bearing…”

Section: Biodistribution Of Nps Following Ip Injectionmentioning

confidence: 99%

“…The authors attributed this clearance profile to the dimensions they found for the lymphatic duct openings (known as stomata) on the diaphragm of mice, which ranged on average from 0.7 to 15.5 µm in length and 0.5 to 8.2 µm in width. Therefore, NPs smaller than these openings were rapidly cleared into the systemic circulation, while a more slow absorption occurred for MPs which were similar in size to the openings [62]. Also, Hirano and Hunt investigated the size effect on the peritoneal retention of liposomes of 48, 170, 460 and 720 nm in rats [63].…”

Section: Biodistribution Of Nps Following Ip Injectionmentioning

confidence: 99%

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Dakwar

Shariati

Willaert

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal carcinomatosis (PC). Over the past decade, a lot of effort has been put both in the academia and clinic in developing IP therapeutic approaches that maximize local efficacy while limiting systemic side effects. Also nanomedicines are under investigation for the treatment of tumors confined to the peritoneal cavity, due to their potential to increase the peritoneal retention and to target drugs to the tumor sites as compared to free drugs. Despite the progress reported by multiple clinical studies, there are no FDA approved drugs or formulations for specific use in the IP cavity yet. This review discusses the current clinical management of PC, as well as recent advances in nanomedicines-based IP delivery.We address important challenges to be overcome towards designing optimal nanocarriers for IP therapy in vivo.

show abstract

“…[26][27][28] NPs or micelles have shown rapid clearance from the peritoneal cavity. 29 Considering the advantages of polymeric thermosensitive hydrogels, in this study, Doc and LL37 were coloaded in polylactic acid (PLA)-Pluronic L35-PLA (PLA-L35-PLA) NPs (Doc+LL37 NPs), and then the Doc+LL37 NPs were dispersed in PLA-L64-PLA (number-average molecular weight [M n ] 4,500) thermosensitive hydrogel to prepare Doc+LL37 NPs-hydrogel composites, and treatment with Doc+LL37 NPs-hydrogel composites in colorectal peritoneal carcinomatosis HCT116 models was evaluated. Our findings indicated that the NP-hydrogel composites improved antiangiogenesis and antitumor activity both in vitro and in vivo, and might have great potential clinical application.…”

Section: Introductionmentioning

confidence: 99%

Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer

Fan

Tong

et al. 2015

IJN

View full text Add to dashboard Cite

Intraperitoneal chemotherapy was explored in clinical trials as a promising strategy to improve the therapeutic effects of chemotherapy. In this work, we developed a biodegradable and injectable drug-delivery system by coencapsulation of docetaxel (Doc) and LL37 peptide polymeric nanoparticles (Doc+LL37 NPs) in a thermosensitive hydrogel system for colorectal peritoneal carcinoma therapy. Firstly, polylactic acid (PLA)-Pluronic L35-PLA (PLA-L35-PLA) was explored to prepare the biodegradable Doc+LL37 NPs using a water-in-oil-in-water double-emulsion solvent-evaporation method. Then, biodegradable and injectable thermosensitive PLA-L64-PLA hydrogel with lower sol–gel transition temperature at around body temperature was also prepared. Transmission electron microscopy revealed that the Doc+LL37 NPs formed with the PLA-L35-PLA copolymer were spherical. Fourier-transform infrared spectra certified that Doc and LL37 were encapsulated successfully. X-ray diffraction diagrams indicated that Doc was encapsulated amorphously. Intraperitoneal administration of Doc+LL37 NPs–hydrogel significantly suppressed the growth of HCT116 peritoneal carcinomatosis in vivo and prolonged the survival of tumor-bearing mice. Our results suggested that Doc+LL37 NPs–hydrogel may have potential clinical applications.

show abstract

Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel

Abstract: Our results indicate the important roles of drug carrier in determining the peritoneal targeting advantage and antitumor activity of IP treatment.

Cited by 115 publications

References 32 publications

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer

Contact Info

Product

Resources

About